A key mechanism underlying physiological angiogenesis of the human endometrium is its ability to regenerate the vascular capillary network and to perform vascular remodeling (i.e., development of spiral arteries). Vascular endothelial growth factor (VEGF) is associated with angiogenesis and capillary permeability in this tissue. VEGF is expressed as several spliced variants, its main human isoforms contain 121 and 165 aa; 17␤-estradiol (E2) increases endometrial VEGF, possibly in all isoforms. Here we show that progesterone (P) selectively increases the expression of the VEGF189 (V189) isoform in the human uterus. V189 is identified in the conditioned medium of stromal cells treated with E2 ؉ P; its presence in this in vitro model of decidual stromal cells is detected after 6 -8 days, using ELISA, and after 8 -10 days, using Western blot analysis with different antibodies, including one specific for V189. The secretion pattern of V189 parallels that of the decidual protein IGFBP-1. V189 is secreted as a native isoform, as compared with the migration of recombinant V189 by SDS͞PAGE. In situ hybridization and immunocytochemistry, performed on the same biopsies, suggest that decidual cells express V189 during the midlate secretory phase of the menstrual cycle and early gestation. Finally, using an in vivo permeability assay, we show that native V189 increases capillary permeability. These observations demonstrate that P regulates V189 expression in decidual cells, which could have important implications for understanding uterine vascular remodeling and implantation, and may be relevant in a range of disease states such as edema and irregular bleeding.
A key mechanism underlying physiological angiogenesis of the human endometrium is its ability to regenerate the vascular capillary network and to perform vascular remodeling (i.e., development of spiral arteries). Vascular endothelial growth factor (VEGF) is associated with angiogenesis and capillary permeability in this tissue. VEGF is expressed as several spliced variants, its main human isoforms contain 121 and 165 aa; 17␤-estradiol (E2) increases endometrial VEGF, possibly in all isoforms. Here we show that progesterone (P) selectively increases the expression of the VEGF189 (V189) isoform in the human uterus. V189 is identified in the conditioned medium of stromal cells treated with E2 ؉ P; its presence in this in vitro model of decidual stromal cells is detected after 6 -8 days, using ELISA, and after 8 -10 days, using Western blot analysis with different antibodies, including one specific for V189. The secretion pattern of V189 parallels that of the decidual protein IGFBP-1. V189 is secreted as a native isoform, as compared with the migration of recombinant V189 by SDS͞PAGE. In situ hybridization and immunocytochemistry, performed on the same biopsies, suggest that decidual cells express V189 during the midlate secretory phase of the menstrual cycle and early gestation. Finally, using an in vivo permeability assay, we show that native V189 increases capillary permeability. These observations demonstrate that P regulates V189 expression in decidual cells, which could have important implications for understanding uterine vascular remodeling and implantation, and may be relevant in a range of disease states such as edema and irregular bleeding.
A s a tissue that exhibits rapid cyclic changes (1) , the human endometrium is a good model for the study of physiological angiogenesis, which is under the control of 17␤ estradiol (E 2 ), progesterone (P), and vascular endothelial growth factor (VEGF) (2) (3) (4) (5) (6) (7) .
VEGF is a protein with angiogenic activity and is a potent stimulator of microvascular permeability (8, 9) ; it plays an important role in physiological and pathological neovascularization, via its receptors Flt-1͞VEGFR1 and Flk-1͞VEGFR2 (10) (11) (12) (13) . Molecular cloning of the cDNA for VEGF revealed that differential exon splicing generates several isoforms containing 121, 165, 189, and 206 aa (V 121, V 165, V 189, and V 206 ) (14, 15) . In most systems V 121 and V 165 are the major species expressed, whereas V 189 is only minimally present and V 206 is limited to embryonic tissue (9, 15) . The different isoforms appear to have similar functions, but differ in their binding affinity for extracellular matrix (ECM). In contrast to VEGF 121 , which is secreted and found freely soluble in the culture medium, the bioavailability of VEGF 165 and to a greater extent V 189 appears to be regulated by binding to heparan sulfate proteoglycans (HSPG) in the ECM (9, 16) . Bound VEGF isoforms could provide a reserve of growth factors available after cleavage by heparinase or urokinase-type plasminogen activator (uPA) (17, 18) .
Previous studies have reported cycle-dependent changes in VEGF expression in the human uterus (5-7). V 121 and V 165 mRNA predominate in the uterus; E 2 increases VEGF expression, possibly of all VEGF isoforms, in the endometrium and isolated endometrial cells (2, 4-7, 19, 20) . In contrast, the role of P in endometrial angiogenesis and stromal swelling necessary for embryo implantation has not been elucidated. However, the possibility exists that progestins can affect VEGF expression (6, 7, 21, 22) or bioavailability. Whether the three VEGF isoforms have identical biological functions in the uterus is not clear at present.
In this study, we show that P increases endometrial V 189 during the secretory phase of the menstrual cycle. By immunocytochemistry and in situ hybridization we localize the V 189 isoform in the decidual cells of the secretory and pregnant endometrium.
Using an in vitro model of stromal cells treated with E 2 ϩ P for 14 days to mimic the secretory phase, we demonstrate that the secretion of native V 189 is correlated with decidualization. In vivo studies demonstrate that V 189 modulates capillary permeability (CP). These findings suggest that P by its action on decidual cells modulates the vascular permeabilization necessary for implantation and possibly for the maintenance of pregnancy.
Experimental Procedures
Hormones and Reagents. E 2 and P were provided by Sigma and EGF by PreproTech (Rocky Hill, NJ). Recombinant VEGF proteins (V 165 and V 189 ) and antibodies against V 189 (P2 directed to the sequence corresponding to exon 6) have been described (18) . A mouse-specific anti-V 189 antibody was also prepared by immunization with three s.c. injections of 5 g V 189 in Freund's adjuvant. IgG were purified by protein A Sepharose (Pharmacia), chromatographed on a V 165 affinity column (CnBr Sepharose, Pharmacia), and the flow-through was dialyzed against PBS. The specificity of the antibody for V 189 was confirmed by ELISA on V 165 and V 189 coated plates and Western blot analysis (not shown).
Human Biopsies. Human endometrial biopsies were obtained from consenting women investigated for infertility (23, 24) without any apparent endocrinological problems or local organic pathol-ogy. The specimens were in the proliferative (n ϭ 10) and secretory (n ϭ 15) phases of the cycle. A few samples were obtained from women undergoing voluntary termination of pregnancy. Tissues were either frozen in isopentane precooled in liquid nitrogen, or fixed in 4% paraformaldehyde and paraffin-embedded. Biopsies were also obtained from premenopausal cycling women undergoing hysterectomy for benign nonendometrial pathology (7) . Tissues were immediately placed into DMEM containing 10% FCS and 1% antibiotic-antimycotic solution, and processed for stromal cell preparation.
Isolation and Treatment of Human Endometrial Cells. Stromal cell isolation was performed as described (7, 25) . The purity of the cell preparation was verified at passage 3-4 by using an antivimentin antibody (7) . Stromal cells were grown in DMEM͞10% FCS until confluent. Before steroid stimulation, cells were cultured for 2 days in phenol red-free DMEM͞3% stripped FCS, and overnight in 0.3% stripped FCS. Hormones (E 2 , 10 Ϫ8 M; P, 10 Ϫ6 M) were added in phenol red-free DMEM in the presence of 5% apo-transferrin, 0.1% ascorbate, and 20 ng͞ml EGF for 1-14 days (23) . Control cells were incubated in the same medium without hormone.
Extraction of RNA from Cells and Semiquantitative Reverse Transcription (RT)-PCR. Confluent cells were scraped into lysis buffer by using the TRIzol reagent kit (GIBCO͞BRL). RT was performed as described (7) . RT-PCR was performed using primers derived from the human VEGF sequence (positions 335 and 698, ref. 21) as described (26) , using an annealing temperature of 56°C. The relative concentrations of VEGF transcripts in stromal cells from different groups was determined using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA as internal standard and [␥-33 P]ATP as described (26) . Bands were visualized and quantified on a Instant Imager (Hewlett-Packard). Two RT and two PCR͞RT were performed for each experiment. Data were analyzed from six independent experiments and statistical analysis was performed using a two-way ANOVA test.
Immunocytochemistry. VEGF immunocytochemistry (ICC) was performed on paraffin sections by using a rabbit antibody raised against the first 20 aa of human VEGF (VEGF A20, Santa Cruz Biotechnology; 1͞250 dilution), followed by incubation with biotinylated anti-rabbit IgG and streptavidin peroxidase (Dakopatts, Glostrup, Denmark) (7). The latter was reacted with amino-ethylcarbazole. Antibodies against smooth ␣-actin (Dakopatts; refs. 27 and 28) and TIMP-3 metalloproteinase inhibitor (Oncogene Science) were used to detect specific decidual cell components. VEGF 189 was detected on frozen sections by using a mouse-specific anti-V 189 antibody (10 g͞ml). Controls included incubation of sections with irrelevant rabbit or mouse IgGs.
Immunoprecipitation. The culture medium was collected every 48 h from confluent stromal cells stimulated with E 2 ϩ P and used after concentration (Amicon) or immunoprecipitation with magnetic beads coated with sheep anti-rabbit IgGs (Dynabeads M-280, Dynal, Great Neck, NY) (29) . Beads were incubated overnight at 4°C with VEGF antibody (A-20; P2 antibody; 1 g antibody for 4 ϫ 10 7 beads) in PBS͞1% skim milk, followed by overnight incubation at 4°C with 50 g proteins from different conditioned media, in the presence of protease inhibitors (pepstatin 1 g͞ml, leupeptin 5 g͞ml, antipain 5 g͞ml, and aprotinin 1 g͞ml). Bound proteins were eluted from beads by boiling in 25 l of SDS͞PAGE sample buffer.
Immunoblotting of VEGF. Proteins were separated by 12% SDS͞ PAGE under reducing conditions (DTT, 100 mM; iodoacetamide, 50 mM) and transferred onto polyvinylidene difluoride membrane (Polyscreen NEN Life Science Products). Rabbit anti-VEGF antibodies (A-20, 2 g͞ml; P2, 1 g͞ml) were used to detect VEGF. In some experiments, membranes were incubated with mouse anti-VEGF antibody (clone 26503, R & D Systems; 5 g͞ml) and rabbit anti-IGFBP-1 antibody (Upjohn Pharmacia, 1͞1,000 dilution).
Enzyme Immunoassay for VEGF. All VEGF isoforms were measured using Quantikine ELISA kit (R & D Systems). The presence of V 189 was also specifically detected using P2 antibody in an ELISA assay (18) .
In Situ Hybridization. In situ hybridization was performed on endometrial paraffin sections as described (30) . The slides were hybridized overnight at 42°C with sense or antisense oligonucleotide probes specific for all VEGF transcripts (sequence corresponding to exon 4) or only V 189 transcripts (sequence corresponding to exon 6) (15); exon 4 sense probe, 5Ј-CTCACCAAGGCCAGCACATAGGAGAGATGA-3Ј; antisense probe, 5Ј-TCATCTCTCCTATGTGCTGGCCTTGGT-GAG-3Ј; exon 6 sense probe, 5Ј-GCAAGAAATCCCGGT-ATAAGTCCTGGAGCG-3Ј; antisense probe, 5Ј-CGCTC-CAGGACTTATACCGGGATTTCTTGC-3Ј; these probes were labeled with [ 35 S]ATP at the 3Ј end by using terminal deoxynucleotidyl transferase. After hybridization (30) , the slides were exposed with photographic emulsion for 3-5 weeks.
Vascular Permeability Assay. The Miles vascular permeability assay (31, 32) was adapted to Wistar rats as follows. Adult male Wistar rats (body weight 300-500 g) (CERJ Janvier, Le Genest St. Isle, France) were anesthetized with pentobarbital (50 mg͞kg i.p.) and their backs closely shaved. Animals were then given filtered Evans-Blue solution (0.5%) via the left jugular vein. Twenty minutes later, native and cleaved recombinant V 189 (18) or recombinant V 165 were injected at 1-50 ng per injection (0.1 ml) intradermally into the back of the rat. Saline solution and 100 M histamine were used as controls. The antiprotease aprotinin (100 nM) and a polyclonal anti-uPA antibody (gift from E. Angles Cano, INSERM, Paris; 50 g͞ml) were added to native V 189 in some experiments. The increase in CP was assessed by the leakage of dye bound to the serum proteins, giving an intense blue spot surrounding the injection site. The size of the different spots was measured 15 min after injection.
Results
We have previously described the modulation of VEGF expression in the human endometrial functional layer throughout the menstrual cycle and its induction by sex steroid hormones in isolated human stromal cells (7) . The steady-state expression of VEGF transcripts was increased by E 2 within 1-3 h and persisted for 12 days, whereas P for 1-24 h did not modify VEGF mRNA levels. To further analyze the role of P on VEGF expression, subconfluent cultures of endometrial stromal cells were treated for 14 days with E 2 ϩ P; these cells express estradiol and progesterone receptors (7, 34) .
Human Endometrial Stromal Cells Treated with Estradiol and Proges-
terone Express V189 mRNA in Vitro. Northern blot analysis of RNA extracted from E 2 ϩ P-treated cells detected no significant changes in VEGF transcripts during the time course of stimulation (1-14 days) (data not shown). Using RT-PCR and oligonucleotides derived from exons shared by every VEGF mRNA species, 108-, 240-, and 312-bp fragments, corresponding to the mRNA encoding V 121 , V 165 , and V 189 , were amplified. The major amplified species corresponded to V 121 and V 165 (Fig. 1) . Using a semiquantitative RT-PCR assay (see Experimental Procedures), the level of expression of V 189 transcripts was usually not increased in stromal cells incubated with EGF ϩ E 2 ϩ P for 1-14 days ( Fig. 1) (n ϭ 4) , except in one experiment where a small increase (ϫ2, P Ͻ 0.01) was observed at 14 days. Altogether, these data indicate no significant change in V 189 mRNA levels in stromal cells incubated with E 2 ϩ P for 14 days.
In Vitro Decidualized Cells Express V189 Protein.
To analyze the production of VEGF isoforms by stromal cells during the E 2 ϩ P treatment, the conditioned medium was analyzed by Western blot and ELISA. Analysis by ELISA using anti-VEGF antibody that recognizes all isoforms revealed that VEGF was secreted throughout the duration of culture. Using a specific anti-V 189 recognizing antibody (P2), the presence of V 189 was detected in the conditioned medium after 6-8 days of cell treatment with EGF ϩ E 2 ϩ P (Table 1 ) or E 2 ϩ P (data not shown); in contrast, it was not secreted by cells in the absence of P. Western blot analysis with two different anti-VEGF antibodies (A-20 and clone 26503) reproducibly detected a major protein band, approximately 29-30 kDa, in the conditioned medium from cells treated with EGF ϩ E 2 ϩ P or E 2 ϩ P for 10-12 days, corresponding to native V 189 (Fig. 2 A and C) . V 189 was detectable over 4-6 days, starting on day 8 or 10 depending on the endometrium; it was not detected before day 8, or was present in small amounts under E 2 treatment (Fig. 2 A) . Two minor bands, 22-23 and 18 kDa corresponding to V 165 and V 121, were strongly detected under E 2 treatment but were present in smaller amounts under E 2 ϩ P treatment (Fig. 2 A Upper) . The specificity of the 30-kDa band was ascertained when proteins of the conditioned medium were immunoprecipitated using anti-V 189 antibody (P2), then immunoblotted with anti-VEGF antibodies (Fig. 2B) .
We then investigated whether the V 189 -expressing stromal cells are decidual cells and secrete IGFBP-1, as decidual cells are known to secrete this protein in the secretory phase and under P treatment (33) . The increase in V 189 in the conditioned medium of stromal cells treated with EGF ϩ E 2 ϩ P for [8] [9] [10] [11] [12] days was parallel to the increase in IGFBP-1 (Fig. 2 A) . Thus, endometrial stromal cells decidualized in vitro under P treatment secrete V 189 mRNA and protein (Table 1) .
V189 Is Expressed in the Human Endometrium During the Luteal Phase
and Pregnancy. Immunostaining for VEGF correlates with total production and bioavailability when commercially VEGF antibodies that cannot distinguish between the different isoforms are used. During the proliferative and early-secretory periods a faint staining for VEGF was observed in endometrial stromal cells, along with diffuse interstitial staining (Fig. 3A and refs. 5-7) . During the late secretory period, although not previously described (5-7), VEGF labeling was strongly present in the round perivascular stromal cells as shown in Fig. 3B . These cells express smooth ␣-actin (Fig. 3C) , typical of predecidual cells. To confirm the localization of V 189 in the luteal phase, endometrial sections were incubated with a mouse-specific anti-V 189 antibody. As shown in Fig. 3E , V 189 isoform was localized in decidual cells during the luteal phase.
We next used in situ hybridization to confirm V 189 mRNA expression in human decidual stromal cells; endometrial sections were incubated with oligonucleotide probes covering the exon 6 specific to V 189 , or the exon 4 present in all VEGF transcripts. As shown in Fig. 4 A-D, V 189 transcripts were observed during the mid-late secretory period and early gestation in perivascular decidualized cells; control studies using sense probe (Fig. 4D   Fig. 1 . Expression level of VEGF transcripts in stromal cells incubated with both estradiol and progesterone. Total RNA was extracted every 2 days from cells subjected to EGF ϩ E 2 ϩ P for 14 days. This figure shows an ethidium bromide gel of RT-PCR analysis from stromal cells incubated with hormones for 4, 8, and 14 days. The conditioned medium from stromal cells was analyzed every 2 days for the presence of V 189 and IGFBP-1, using Western blot (WB) and ELISA assay. Inset) indicated that the hybridization signal seen in Fig. 4 A-D represents specific binding to V 189 transcripts. VEGF mRNAs corresponding to all isoforms were expressed at moderate levels in stromal cells throughout the menstrual cycle (Fig. 4 E and F) . Altogether, immunocytochemistry (ICC) and in situ hybridization on the same biopsies demonstrate that the enhanced expression of V 189 mRNA during the mid-late secretory period (days 24-28) corresponds to a high level of VEGF, probably the 189 isoform, produced in groups of perivascular decidual cells (Table 2) .
The development of a stromal basement membrane [consisting of laminin, fibronectin, heparan sulfate proteoglycans (HSPG), and type IV collagen] at the end of decidualization (days 24-25, refs. 35 and 36) suggests that V 189 could anchor at it during this period. As expected, expression of type IV collagen and HSPG was observed in predecidual cells at day 25, whereas it was mainly confined to the vascular subendothelial basement membrane before days 22-23 (data not shown). The development of a basement membrane by decidual cells in vitro, as deduced from the immunostaining of the decidual marker TIMP-3 (data not shown), correlates with the absence of V 189 secretion observed after day 14 (Fig. 2 A) .
V189 Increases CP.
The strong expression of V 189 by perivascular decidual cells suggests that P and V 189 play a role in the physiological differentiation and function of the endometrial vessels during the mid-late secretory phase, as previously suggested (7) . Different expression of VEGF receptors during the implantation or mid-late secretory periods (24) supports a physiological role for endometrial V 189 . We next tested whether native V 189 secreted by decidual cells could alter CP, as previously described for VEGF in rat uterus (19) .
VEGF effect on CP was analyzed using the Miles assay (31, 32) adapted for use in the rat. Intradermal injection of V 189 (1-50 ng) produced a large increase in CP compared with the control vehicle saline (Fig. 5) ; dose-response studies indicated that maximum induction occurs with 50 ng, as assessed by the area of diffusion of blue dye in the bleb. Both native (Fig. 5A ) and cleaved (data not shown) V 189 increased CP at 1 ng. V 165 and histamine also strongly increased CP. Preincubation of V 189 or V 165 with neutralizing anti-VEGF antibody inhibited VEGFmediated CP, as compared with V 189 or V 165 alone used at the same dose (Fig. 5 B and C) . Addition of aprotinin or an anti-uPA antibody with native V 189 did not significantly change the CP Immunocytochemical staining for VEGF or type IV collagen was evaluated semiquantitatively on endometrial sections, as described (24, 34) .
increase (data not shown), indicating that cleavage by endogenous rat proteases is not required for the CP effect.
Discussion
Although previous studies have shown that E 2 regulates the expression of all VEGF transcripts in endometrial cells (3) (4) (5) (6) (7) 20) , the expression and modulation of VEGF isoforms during human implantation and decidualization is not yet elucidated. The present study demonstrates considerable expression of the V 189 isoform in the human endometrium (functional layer) during the mid-late secretory phase. Using various approaches we have shown that V 189 is up-regulated by P in decidual (stromal) cells, both in vivo and in vitro, supporting an important role of this isoform in the control of angiogenesis. Functional studies demonstrate that V 189 is a potent permeability factor in vivo.
V189 Expression in the Human Endometrium.
In situ hybridization in endometrial samples indicates the presence of V 189 mRNA in a subset of perivascular stromal cells during the mid-late secretory phase, suggesting that the expression of V 189 mRNA may be temporarily and spatially increased. This result extends previous reports showing that V 121 and V 165 are the predominant forms produced at the mRNA level in the uterus (3, 5, 7) . Consistent with our in situ observations, relative expression levels of immunoreactive VEGF isoforms and specific V 189 increase in perivascular stromal cells during the same period, in contrast to the diffuse staining in the stroma observed in proliferative and early-mid secretory endometrium (5-7) ; the difference between faint stromal staining and presence of VEGF transcripts in stromal cells during the menstrual cycle was initially interpreted to be a consequence of differences in the sensitivity between immunocytochemistry (ICC) and RT-PCR analysis or in situ hybridization. However, a less-defined localization pattern with ICC could result from the production by the stromal cells of the more diffusible variants of VEGF, V 121 and V 165 (9) . Our data clearly indicate that the strong V 189 immunostaining observed in clusters of decidual cells during the mid-late secretory phase corresponds to a local high level of expression of V 189 mRNA, suggesting that these mRNA are indeed translated into proteins in these cells.
In Vitro Decidualized Cells Express V189 Protein. V 189 was shown by Western blot and ELISA to be secreted in vitro during the E 2 ϩ P-dependent differentiation of stromal into decidual cells secreting IGFBP-1, as deduced from the analysis of both proteins from the same medium and the use of specific antibodies. In vitro studies on stromal cells also indicate that V 189 is secreted as an uncleaved isoform (28-30-kDa monomer) in response to E 2 ϩ P. This finding correlates with a low level of uPA expression that has been shown to cleave V 189 (17, 18) , and with the increase in the expression of plasminogen activator inhibitor-1 (PAI-1) in the same cells under the same conditions (38) .
Although V 189 was originally described as an isoform anchored to the basement membrane (17, 18) , the secretion of V 189 by endometrial stromal cells is not surprising, because these cells do not produce a pericellular basement membrane until complete decidual transformation (ref. 1 and unpublished observations). Stromal decidualization begins by day 22 or 23 in the perivascular areas of the functional layer, increases on day 24, and is achieved by day 25. During their differentiation from mid-secretory phase to the end of pregnancy, predecidual cells sequentially express and secrete relaxin, prolactin, and IGFBP-1 (33), change their morphology in association with the appearance of smooth muscle ␣-actin (ref. 28 and this study), and express progesterone and estrogen (ER␤) receptors (27, 34) . The presence of type IV collagen, heparan sulfate proteoglycans (HSPG), and TIMP-3 during the mid-late secretory phase (days 24-26) (unpublished observations) reflects the production and assembly of a distinct pericellular basement membrane by differentiated decidual cells (35) (36) (37) . The decrease in V 189 secreted by decidual cells observed around 14 days of culture with E 2 ϩ P, while IGFBP-1 was still secreted (Fig. 2 A) , argues in favor of progressive anchoring of V 189 to the basement membrane at the end of the cycle (see Tables 1 and 2 ). Thus, V 189 could modulate vascular function according to its release or sequestration in the cell basement membrane. In addition, it is possible that E 2 or P may modulate the expression of proteins and proteoglycans that sequester V 189 .
Progesterone Regulation of V189. There are a few reports that progestins can modulate VEGF production by human endometrial and breast cancer cells (6, 7, 39, 40) , and these effects have been less studied than those of estrogens (41) . Results on monkey endometrium treated for 20 days with levonorgestrol support the hypothesis that progestins can modulate V 189 gene expression in primate endometrium (21) . In the present study, we consistently observed an increase in V 189 protein expression in long-term E 2 ϩ P-treated human endometrial stromal cells (with no consistent increase in V 189 mRNA levels). Although substantial differences may exist between cell types and in different species, the strong increase in V 189 protein secreted from endometrial decidual cells, as compared with V 121 and V 165 and irrespective of their relative transcript levels, suggests another mechanism of regulation, possibly at the level of translation.
Physiologic Implication of V189 Expression in Endometrium. Neovascularization in normal endometrium is indirectly modulated by ovarian steroids, via the production of locally active angiogenic factors such as VEGF (6, 7) , which is mitogenic for endothelial cells (9, 10) , through its receptors (10-13, 24, 42) . E 2 and E 2 ϩ progestin (such as P or medroxyprogesterone acetate) cause a marked increase in VEGF mRNA accumulation, correlating with a high vascular density during the late proliferative phase and between cycle days 18-22 (i.e., during the implantation window) (6, 7) , where it is associated with a high level of expression of VEGFR1 and VEGFR2 (24) . However, some evidence exists to support a role of certain progestins as antiangiogenic factors in vitro (reviewed in ref. 40 ). P-induced V 189 expression by perivascular decidual cells correlates with its binding to endometrial vessels and with a switch of endothelial VEGF receptors (decreased ratio of VEGFR2͞VEGFR1) and ER subtype (increase in ER␤) during the mid-late secretory phase (24, 27) , suggesting that V 189 plays a role in the physiological differentiation and function of the endometrial vessels. Human endometrial decidualization is associated with vascular remodeling such as development of spiral arteries, inhibition of angiogenesis, and sustained CP (1). Also, a marked increase in the expression of PAI-1 and an inhibition of uPA expression accompany progestin-induced decidualization in vivo and in vitro. Our results suggest that V 189 could function either in its native form, which binds to VEGFR1, or in its cleaved form, which binds to both VEGFR1 and VEGFR2 (the latter mediating the VEGF-dependent mitogenic effect), depending of the presence of proteases (18) . Our results further suggest that secretion of native V 189 during the mid-late secretory phase in the absence of uPA can alter CP (and possibly other functions) without inducing angiogenesis. In contrast, V 189 could be cleaved by uPA during steroid hormone removal resulting in menstruation. Also, the increase in CP induced by V 189 provides an explanation for the episodes of endometrial capillary rupture and irregular bleeding associated with progestin-based contraceptives and hormonal substitutive treatments (43) .
Thus, endometrial development in the primate represents a physiological model for differential expression and function of VEGF isoforms (especially V 189 ) and their receptors. Our data also suggest that VEGF isoforms derived from specific splice variants can have unique functions, depending on their tissue origin. Also, the possibility remains that other unknown tissuespecific vascular factors might be involved in human reproduction biology, such as the endocrine-gland-derived VEGF (EG-VEGF) specifically reported in fenestrated capillary endothelial cells from endocrine glands (44) . Another model utilizes transformed cells nullizygous for VEGF to specifically express each of these isoforms and determine their role in tumorigenic neovascularization (45) . Mouse V 188 -expressing tumors failed to grow, because of little or no recruitment of the host vasculature. Further studies are in progress in our laboratory to analyze other tissue localizations and functions of the V 189 isoform.
